PATIENT HANDBOOK
A Publication of the International Myeloma Foundation

Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.

Multiple Myeloma
Cancer of the Bone Marrow

Prepared by Brian G.M. Durie, M.D.
2012/2013 Edition

Improving Lives • Finding the Cure
One of the most daunting aspects of being diagnosed with multiple myeloma (MM) is learning about – and understanding – an unfamiliar disease that is quite complicated. From diagnosis to long-term survival, the 10 Steps to Better Care™ will guide you through the MM journey:

1. Know what you’re dealing with. Get the correct diagnosis.
2. Tests you really need.
3. Initial treatment options.
4. Supportive care and how to get it.
5. Transplant: Do you need one?
6. Response Assessment: Is treatment working?
7. Consolidation and/or maintenance.
9. Relapse: Do you need a change in treatment?

Visit 10steps.myeloma.org to gain a better understanding of the disease and diagnosis, and proceed through the steps to learn the best tests, treatments, supportive care, and clinical trials currently available.

As always, the International Myeloma Foundation (IMF) urges you to discuss all medical issues thoroughly with your doctor. The IMF is here to equip you with the tools to understand and better manage your MM. Visit the IMF website myeloma.org or call the IMF Hotline at 800-452-CURE (2873), which is staffed by trained information specialists, with your questions or concerns. The IMF is here to help.
Table of Contents

Introduction 4

Step 1: Know what you’re dealing with. Get the correct diagnosis. 4

What is Myeloma? 4

Basic Facts About Myeloma 5

Why Myeloma Must Be Treated 6

What Causes the Medical Problems with Myeloma 7

Step 2: Tests you really need. 7

Different Types of Myeloma 7

Staging of Myeloma 8

Testing at Diagnosis 11

Step 3: Initial treatment options. 11

Initial or Frontline Therapy 11

Step 4: Supportive care and how to get it. 12

If Frontline Therapy is Not Working 13

Questions to Ask Your Doctor 13

Terms and Definitions 17

About the International Myeloma Foundation 27
Introduction
The International Myeloma Foundation (IMF) is committed to providing education and support for patients and families.

One of the most daunting aspects of being diagnosed with multiple myeloma (MM) is learning about – and understanding – an unfamiliar disease that is quite complicated. Patients and their loved ones often feel as if they’ve stepped through the looking-glass and are in a world where their old vocabularies no longer work. The International Myeloma Foundation (IMF) Patient Handbook is meant to be your guide through this “new world,” and to furnish you with the tools to understand and better manage your myeloma.

The IMF Patient Handbook focuses on what to do when myeloma is first discovered, and therefore covers the first four of the 10 Steps to Better Care™. More details about such topics as transplantation, supportive care, individual drugs, what to do at relapse, and clinical trials are available in other booklets at myeloma.org. For any questions or concerns, the IMF Hotline is available via email at TheIMF@myeloma.org or by calling 800-452-CURE (2873), toll-free in the US and Canada, or 818-487-7455 from other parts of the world. Please call! The IMF is here to help.

Step 1: Know what you’re dealing with. Get the correct diagnosis.

What is Myeloma?
Multiple myeloma is a bone marrow cancer. The intent of this booklet is to provide basic information and suggestions about how to cope with this disease.

Although there is currently no cure for myeloma, it is an eminently treatable disease. Many patients go on to lead full and productive lives for years, even decades, after diagnosis. With increasing research, the overall outlook for patients is improving steadily. Knowing more about the disease, and understanding what can be done to help, reduces anxieties and makes it easier to come to terms with the diagnosis.

Myeloma is a very individual disease. Myeloma is often slow-moving, but can also sometimes be much more aggressive. A skilled myeloma specialist will be able to determine the best approach in your individual situation. If you do not have a myeloma specialist nearby, you can find a specialist who will work with a local doctor administering your care. While your healthcare team assesses each particular situation and recommends the best approach, the patient plays a central role in helping make these individual treatment decisions. It is important that patients and their families be well informed, ask questions, and give serious thought to alternative strategies or options. A key IMF message is “Knowledge is Power.” Knowing about your disease helps you to make the best decisions.

Myeloma is literally an “oma,” or tumor, involving the “myelo,” or blood-producing cells in the bone marrow. The cells that are affected are plasma cells (a type of white blood cell), which are our antibody-producing (immunoglobulin-producing) cells. A malignant or cancerous plasma cell is called a myeloma cell. Myeloma is called “multiple” since there are frequently multiple patches or areas in bone where it grows. Myeloma can appear as both a tumor and/or an area of bone loss. In either case, the tumor or hole in the bone is called a “lesion.” Areas of bone loss caused by myeloma are referred to as “lytic lesions.” The only time that myeloma is not “multiple” is in the rare case of a “solitary plasmacytoma,” a single myeloma tumor that may appear either inside or outside the bone marrow.

Myeloma affects the places where bone marrow is normally active in an adult. This marrow is in the hollow area within the bones of the spine, skull, pelvis, the rib cage, and the areas around the shoulders and hips. The areas usually not affected are the extremities: the hands, feet, and lower arm/leg regions. This is very important, since the function of these critical areas is usually fully retained.

Myeloma can be discovered at a precancerous stage (see Table 1). In some cases, the myeloma cells build up very slowly in the bone marrow. The very earliest stage is called Monoclonal Gammopathy of Undetermined Significance (MGUS). This is not a cancer. In MGUS, the myeloma cells constitute
fewer than 10% of the bone marrow cells. The risk of transition from MGUS to active myeloma is very low: only a 1% chance each year of follow-up. Even if the myeloma cells are at a higher level of 10–30% of the total bone marrow, the growth rate can be very slow and represent indolent/smoldering or asymptomatic myeloma. Both MGUS and indolent myeloma can change very slowly over a period of years and do not require active treatment. It is very important to establish the correct diagnosis distinguishing MGUS and indolent myeloma from active or symptomatic myeloma, which does require treatment.

**Basic Facts About Myeloma**

Several things are capable of causing myeloma or triggering an already abnormal or damaged pre-myeloma cell population in the bone marrow. Several types of things can cause or trigger myeloma: exposure to toxic chemicals, atomic radiation, anything suppressing or interfering with the immune system, or infection with cancer-causing viruses. Toxic chemicals which have been identified include benzene, dioxins (such as dioxins in Agent Orange), and a whole range of agricultural chemicals, solvents, fuels, engine exhausts, and cleaning materials. Serious radiation exposure is rather uncommon, but has occurred in Japan at atomic test and reactor sites, as well as manufacture facilities. Several viruses have been identified, including HIV (AIDS virus), hepatitis viruses, and several herpes viruses. Some retroviruses, such as SV40 (Simian Virus 40), a contaminant in polio vaccine preparations, have also been implicated in the pathogenesis of myeloma.

There is some family tendency for myeloma: approximately 3–5% of myeloma diagnoses occur in a family member who has a close relative previously diagnosed with MGUS or myeloma. Potential screening/early testing can be discussed with your physician if you have a family member with myeloma or MGUS.

**Myeloma occurs in adults.** The average age of onset of myeloma is in the early to mid-60s.

Only 5–10% of patients are under the age of 40 years. Myeloma occurs more commonly in men and in some racial groups, such as African-Americans.

**There are approximately 20,000 new cases of myeloma in the U.S. each year.** The incidence ranges from ~0.5–1/100,000 among Asians to as high as ~10–12/100,000 among African-American men. It appears that the incidence of myeloma is increasing in several parts of the world, especially in Asia. At any one time there are over 100,000 myeloma patients undergoing treatment for their disease in the US.

---

**TABLE 1: Definitions of MGUS and Myeloma**

<table>
<thead>
<tr>
<th>NAME</th>
<th>DEFINITION</th>
</tr>
</thead>
</table>
| **Monoclonal Gammopathy of Undetermined Significance (MGUS)** | • Monoclonal protein present but usually <3.0 g/dL  
• No CRAB features or other indicators of active myeloma  
• Bone marrow monoclonal plasma cells <10%                                                                 |
| **Asymptomatic or Smoldering Multiple Myeloma (SMM)** | • Higher level of disease than MGUS: serum m-component can be >3.0 g/dL  
and/or bone marrow plasma cells >10%, but  
• No CRAB features or other indicators of active myeloma                                                                 |
| **Active or Symptomatic Myeloma**                   | • Monoclonal protein present, and  
• One or more “CRAB” features and/or indicators of organ damage*  

*Organ damage classified as “CRAB” or any other significant clinical problem linked to myeloma progression such as recurrent infections or neuropathy unrelated to treatment.

- **C** — calcium elevation (>10 mg/dL)
- **R** — renal dysfunction (creatinine >2 mg/dL)
- **A** — anemia (hemoglobin <10 g/dL or >2g/dL decrease from patient’s normal)
- **B** — bone disease (lytic lesions or osteoporosis)

One or more “CRAB” features or other significant problem required for diagnosis of Symptomatic Myeloma
Why Myeloma Must Be Treated

Myeloma, if left untreated, can cause a number of medical problems, including: bone damage, elevated blood calcium, low blood counts (especially anemia), predisposition to infection, and kidney damage. Because the bones of the spine are often affected and because myeloma proteins produced by myeloma cells can damage nerves, it is common to have spine and nerve problems that may require urgent attention.

In starting treatment for myeloma, it is important to distinguish between urgent problems such as bone damage, infection, kidney damage, or nerve pressure, which need immediate attention, versus overall planning to treat the disease. Sometimes urgent care cannot and should not be delayed. However, we encourage early consultation with a hematologist/oncologist familiar with myeloma. For example, options of emergency surgery versus radiation therapy can be discussed. Also, making sure that all treatment options are kept open for the future is an important consideration.

Once urgent matters have been dealt with, overall plans can be discussed in more detail. Frequently there is time to seek a second opinion or consultation with an expert to be assured that all options are carefully reviewed. Even if plans seem to be clear, if there are any concerns, questions, or doubts, it is better to have these aired sooner rather than later. Having a mutually agreed-upon plan can help ensure that all aspects of your treatment are well considered.

**TABLE 2: Medical Problems Related to Myeloma**

<table>
<thead>
<tr>
<th>EFFECTS OF INCREASED MYELOMA CELLS IN BONE MARROW</th>
<th>CAUSE</th>
<th>IMPACT ON PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAB criteria</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| C – Increase in blood calcium                     | Release of calcium from damaged bone into bloodstream. | • Mental confusion  
• Dehydration  
• Constipation  
• Fatigue  
• Weakness  
• Renal or kidney damage (R) |
| R – Renal problems – kidney damage                | Abnormal monoclonal proteins produced by the myeloma cells are released into the bloodstream and can pass into the urine and produce kidney damage. High blood calcium, infections, and other factors can also cause or increase the severity of kidney damage. | • Sluggish circulation  
• Fatigue  
• Mental confusion |
| A – Anemia                                        | Decrease in number and activity of red blood cell-producing cells in the bone marrow. | • Fatigue  
• Weakness |
| B – Bone Damage                                   | The myeloma cells activate osteoclast cells, which destroy bone, and block osteoblast cells, which normally repair damaged bone. | • Bone pain  
• Bone swelling  
• Fracture or collapse of a bone  
• Nerve or spinal cord damage |
| Additional types of organ dysfunction             | Local or systemic effects of myeloma, other than CRAB features. | • Neuropathy  
• Recurrent infections  
• Bleeding problems  
• Other individual problems |
| Abnormal immune function                          | The myeloma cells reduce the number and activity of normal plasma cells capable of producing antibodies against infection. | • Susceptibility to infection  
• Delayed recovery from infection |
plan with your physician for ongoing treatment is tremendously important.

**What Causes the Medical Problems with Myeloma**

Healthy plasma cells produce immunoglobulins, which are complex proteins that we call “antibodies.” Myeloma cells do not make normal functioning antibodies, but instead produce an abnormal immunoglobulin, which is known as a “monoclonal protein.” This diversion of the immune system results in a reduced production of normal antibodies required to fight infection.

Many of the medical problems related to myeloma are caused by the build-up of myeloma cells (see Table 2). However, unlike other types of cancer, myeloma can present patients with many strange complications, because myeloma cells do not just produce tumors, they also release many proteins and other chemicals into the local micro-environment of the bone marrow and directly into the bloodstream.

- **Local effects in the bone marrow.** The effects in the bone marrow include a reduction in blood cell production and damage to the surrounding bone. The net results are the many common features of myeloma, such as anemia, predisposition to infection, bone pain, bone fractures, and elevated blood calcium.

- **Effects outside the bone marrow.** The effects outside the bone marrow are mostly due to the monoclonal protein produced by the myeloma cells. As the myeloma cells build up in the bone marrow, the immunoglobulin or antibody protein that is specific to the myeloma is released into the blood circulation. This specific immunoglobulin protein or monoclonal protein produced by myeloma cells can cause tissue damage at distant sites; for example, kidney damage is quite common. The protein can interfere with blood clotting and/or circulation, and can potentially cause other organ or tissue damage. Treatment for myeloma reduces bone breakdown and tumor growth, as well as these diverse effects from myeloma proteins and chemicals.

**Step 2: Tests you really need.**

**Different Types of Myeloma**

There are different types and subtypes of myeloma. These are based on the type of immunoglobulin (protein) produced by the myeloma cell. Normally, the various immunoglobulins have different functions in the body. Each immunoglobulin protein is made up of two heavy chains and two light chains. (See Figure 1) There are five types of heavy protein chains: G, A, D, E, and M. There are two types of light protein chains: kappa (κ) and lambda (λ or L). The typing of myeloma (done with a test called “immunofixation” [IFE]) identifies both the heavy and light chains. Most myeloma patients, about 65%, have IgG (G) type myeloma with κ or λ light chains. The next most common type is IgA (A) type myeloma, also with either κ or λ light chains. (See Table 3). IgM, IgD, and IgE myelomas are quite rare.

**Figure 1: Immunoglobulin Structure**

- Light Chain (κ or λ)
- Heavy Chain (G, A, D, or E)

Approximately 30% of patients produce free light chains (separate from heavy chains) in addition to the whole molecule combination of light chains plus heavy chains. In about 10% of patients, the myeloma cells produce only light chains and no heavy chains. This is called “light chain” or “Bence Jones” myeloma. Rarely (in about 1–2% of patients), the myeloma cells produce very little or no monoclonal protein of any type. This is called “non-secretory” myeloma. However, the Freelite® test (serum free light chain assay) can detect minute amounts of light chains in the blood of about 70% of these patients.

There are subtle differences in the behaviors of different types of myeloma. IgG myeloma has the usual features of myeloma. The IgA type can sometimes be characterized by tumors outside of the bone. The IgD type can be accompanied by plasma-cell
leukemia and more frequently causes kidney damage. The light chain or Bence Jones myelomas are the most likely to cause kidney damage and/or lead to deposits of light chains in the kidneys and/or on nerves or other organs. Depending upon the characteristics of the light chain deposits, this condition is called either amyloid or light chain deposition disease (LCDD). Two other related diseases of the immunoglobulins are Waldenström's macroglobulinemia, which is associated with IgM monoclonal protein, and POEMS syndrome, an acronym for a rare disease associated with monoclonal protein, neuropathy, enlarged organs, endocrine disorders, and skin changes.

**Staging of Myeloma**

When myeloma is diagnosed, the amount of myeloma in the body varies from patient to patient. This is called the stage of myeloma. The most commonly used clinical staging system, the Durie/Salmon Staging System (DSS) is shown in Table 4, and demonstrates the correlation between the amount of myeloma and the damage caused, such as bone disease or anemia. The “measured myeloma cell mass” for this staging system was calculated from studies in which the amount of myeloma protein (M-protein spike) per myeloma cell was measured; this is called the “M-component synthetic rate.” Studies of body metabolism of M-protein were also conducted, which allowed back calculation to determine the exact number of

### Table 3: Types of Myeloma and Related Diseases

<table>
<thead>
<tr>
<th>DISEASE TYPE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
</table>
| **Myeloma:** | • **Typical myeloma:** majority of patients.  
  IgG κ or λ  
  IgA κ or λ  
  **Rarer subtypes:** 
  IgD, E, or M  
  • Monitored by tracking monoclonal protein in serum using Serum Protein Electrophoresis (SPEP) (IgG) and/or quantitative immunoglobulin (QIG) measurement (IgA/D/E).  
  For IgA myeloma quantitative immunoglobulin measurement is often more reliable. |
| **Light Chain only or Bence Jones (BJ) myeloma:** | • **Bence Jones myeloma:** approximately 15-20% of patients.  
  κ or λ types  
  • Monitored by tracking monoclonal light chains in the urine using Urine Protein Electrophoresis (UPEP) and/or with serum free light chain measurements (Freelite®) in the serum. |
| **Non-secretory myeloma:** | • **Less common myeloma:** 1-2% of patients.  
  κ or λ types  
  • Since both SPEP and UPEP are negative (no monoclonal spike in serum or urine), disease is monitored using Freelite® testing. |
| **IgM myeloma:** | • **IgM myeloma** is a very rare subtype.  
  κ or λ subtypes  
  • Typically, IgM production occurs in a disease called Waldenström's macroglobulinemia, which is more like a lymphoma (lymph node cancer) versus myeloma, which is a bone marrow cancer. |
| **Amyloidosis:** | • **In amyloidosis,** the light chains are deposited in a linear fashion (β-pleated) in tissues rather than being broken down and/or excreted in the urine.  
  AL or immunoglobulin light chain type  
  κ or λ subtypes  
  • There are many varieties of amyloidosis involving deposits of different types of protein.  
  For example, Alzheimer’s disease involves deposits of proteins in the brain.  
  • **In myeloma-related amyloid** light chains can be deposited in many tissues, including skin, tongue, heart, kidneys, nerves, lungs, liver, and intestines.  
  • Tissues stain positive with a “congo red” dye test, which is diagnostic. More detailed testing with mass spectroscopy and/or electron microscopy may be appropriate and necessary. |
| **Light Chain Deposition Disease (LCDD):** | • **In LCDD,** the light chains are deposited in a more disorganized fashion (random cross links).  
  κ or λ subtypes  
  • Tissues stain positively with direct κ or λ immunostaining. Congo red staining is usually negative.  
  • There are different patterns of tissue deposits often involving the lining of the lungs (pleura) or peritoneum (around intestines) or within the eyes. |
| **POEMS syndrome:** | • **POEMS syndrome** is a complex disorder involving polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. Diagnosed and treated differently from myeloma. See text for discussion. |
myeloma cells in the body. This led to the understanding that for some patients who produce a lot of protein, the number of myeloma cells can be quite low. Conversely, in patients with low protein production, the number of myeloma cells can be unexpectedly high. A sense of this relationship can be determined by comparing the percentage of bone marrow myeloma cells with the level of the myeloma protein in the blood and/or urine.

The most commonly used prognostic factor-based staging system (The International Staging System, or ISS) is shown in Table 5, and is the result of the collaboration of more than twenty research institutions worldwide. The prognosis (from the Greek words that mean “knowing ahead”) for myeloma patients is better when treatment is started early and bone disease or other complications can be prevented.

**TABLE 4: The Durie/Salmon Staging System**

<table>
<thead>
<tr>
<th>STAGE</th>
<th>CRITERIA</th>
<th>MEASURED MYELOMA CELL MASS (myeloma cells in billions/m² in whole body)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAGE I (low cell mass)</td>
<td>All of the following: • Hemoglobin value &gt;10 g/dL • Serum calcium value normal or &lt;10.5 mg/dL • Bone x-ray, normal bone structure (scale 0), or solitary bone plasmacytoma only • Low M-component production rates IgG value &lt;5 g/dL; IgA value &lt;3 g/dL • Urine light chain M-component on electrophoresis &lt;4 g/24h</td>
<td>600 billion</td>
</tr>
<tr>
<td>STAGE II (intermediate cell mass)</td>
<td>Fitting neither Stage I nor Stage III</td>
<td>600 to 1,200 billion</td>
</tr>
<tr>
<td>STAGE III (high cell mass)</td>
<td>One or more of the following: • Hemoglobin value &lt;8.5 g/dL • Serum calcium value &gt;12 mg/dL • Advanced lytic bone lesions (scale 3) • High M-component production rates IgG value &gt;7 g/dL IgA value &gt;5 g/dL • Bence Jones protein &gt;12 g/24h</td>
<td>&gt;1,200 billion</td>
</tr>
<tr>
<td>SUBCLASSIFICATION (either A or B)</td>
<td>A: relatively normal renal function (serum creatinine value) &lt;2.0 mg/dL B: abnormal renal function (serum creatinine value) &gt;2.0 mg/dL Examples: Stage IA (low cell mass with normal renal function); Stage IIIB (high cell mass with abnormal renal function)</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 5: International Staging System (ISS) for Multiple Myeloma**

<table>
<thead>
<tr>
<th>STAGE</th>
<th>VALUES</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAGE 1</td>
<td>β2M &lt;3.5 ALB ≥3.5</td>
</tr>
<tr>
<td>STAGE 2</td>
<td>β2M &lt;3.5 AB &lt;3.5 or β2M 3.5 – 5.5</td>
</tr>
<tr>
<td>STAGE 3</td>
<td>β2M &gt;5.5</td>
</tr>
</tbody>
</table>

Note: β2M = Serum β2 microglobulin in mg/L ALB = Serum albumin in g/dL

**TABLE 6: Prognostic Factors**

<table>
<thead>
<tr>
<th>TEST</th>
<th>SIGNIFICANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum β2 microglobulin (S β2M)</td>
<td>The higher the level the more advanced the stage</td>
</tr>
<tr>
<td>Serum Albumin (S Alb)</td>
<td>The lower the level the more advanced the stage</td>
</tr>
<tr>
<td>C-reactive protein (CRP)</td>
<td>Increased with active disease</td>
</tr>
<tr>
<td>Serum LDH (lactate dehydrogenase)</td>
<td>Increased with active disease</td>
</tr>
<tr>
<td>Abnormal chromosomes on bone marrow cytogenetics and FISH (Fluorescent In Situ Hybridization)</td>
<td>Several chromosome deletions or translocations; can be associated with shorter duration of remission</td>
</tr>
<tr>
<td><strong>TEST</strong></td>
<td><strong>PURPOSE</strong></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Bone marrow biopsy</td>
<td>This is the single most critical test to determine both the presence and the percentage of myeloma cells in the bone marrow. In Stage I disease or for a solitary plasmacytoma, direct biopsy of the tumor mass may be necessary. Chromosome analysis (cytogenetic testing) can reveal good or poor chromosomal features using direct (Giemsa stained for banding) and/or FISH analysis. A fresh sample is needed for this type of testing.</td>
</tr>
<tr>
<td><strong>Blood Testing</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Complete blood count (CBC) | • To assess presence/severity of anemia (low hemoglobin)  
• To assess for low white cell count  
• To assess for low blood platelet count |
| Chemistry panel | • Used to assess kidney function (creatinine and BUN), liver functions, albumin, calcium level, and LDH |
| Special protein testing |  |
| Serum protein electrophoresis (SPEP) | • This shows the presence of the monoclonal myeloma protein (“spike” protein)  
• The amount of the abnormal myeloma heavy chain protein |
| Immunofixation | • Shows the type of myeloma protein [i.e., heavy chain (G, A, D or E), light chain, kappa (κ), lambda (λ)] |
| Freelite test | • Can be used to measure the amount of free kappa or lambda light chains if no SPEP or UPEP abnormality discovered |
| **Urine Testing** | Shows the presence, amount, and type of abnormal myeloma protein in urine. |
| Special protein testing similar to serum above:  
• Urine Protein Electrophoresis (UPEP)  
• Immunofixation |  |
| **Bone Testing** | To assess the presence, severity, and location of any areas of bone damage: |
| X-rays | X-rays are still the gold standard in searching for myeloma bone damage. In a majority of patients, X-rays show characteristic myeloma bone disease (lytic lesions or “holes” in the bones). However, X-rays can be negative in approximately 25% of patients with active myeloma and further imaging is needed to rule out possible bone involvement. A full skeletal survey for myeloma using a series of X-rays is needed to show loss or thinning of bone (osteoporosis or osteopenia caused by myeloma bone destruction), lytic lesions, and/or any fracture or collapse of bone. |
| MRI | Used when X-rays are negative and/or for more detailed testing of particular areas such as spine and/or brain. Can reveal the presence and distribution of disease in the bone marrow when X-rays show no bone damage. Can also reveal disease outside of bone, which may be pressing on nerves and/or the spinal cord. |
| CT Scan | Used when X-rays are negative and/or for more detailed testing of particular areas. Especially useful for detailed evaluation of small areas of possible bone damage or nerve pressure. |
| Nuclear Medicine Scans | Routine bone scans used for other cancers. Not useful in myeloma and should not be performed unless ruling out other diagnoses. |
| FDG/PET Scan or PET/CT Scanning | A much more sensitive whole body scanning technique. Useful for disease monitoring, especially for non-secretory disease. CT used to assess sites of PET-positive disease. |
| Bone Density Testing | Helpful to assess the severity of diffuse bone loss in myeloma and to measure the serial improvement with bisphosphonate therapy. |
Several tests can be used to assess how aggressive the myeloma is in a given patient. In general, higher or abnormal test results indicate more active myeloma, and possibly, less likelihood of having a long response with treatment (Table 6). Serum beta 2 microglobulin (β2M), serum albumin (S Alb), C-reactive protein (CRP), and serum lactate dehydrogenase (LDH) are assessed with blood tests. Bone marrow cytogenetics and FISH (Fluorescence In Situ Hybridization) are assessed by special studies done on the bone marrow aspirate sample.

Cytogenetics and FISH are studies of the chromosomal changes that may occur in myeloma cells during cell division. Depending on the presence, absence, and type of changes that occur, a patient’s risk status can be assessed. High-risk abnormalities identified by FISH include deletion of the short arm of chromosome 17 (del 17p); a translocation of genetic material between chromosomes 14 and 16 (t[14;16]); and a translocation between chromosomes 14 and 20 (t[14;20]). Intermediate-risk myeloma by FISH is correlated with a translocation of genetic material between chromosomes 4 and 14 (t[4;14]); and by cytogenetic studies that reveal a loss of chromosome 13 and/or the presence of less than one copy of each chromosome. Standard- or good-risk myeloma is classified by changes including more than one copy of each chromosome; translocation t(11;14); and translocation t(6;14).

As further experience is gained with novel combinations with or without autotransplantation, it is likely that the better predictors will become available. It is important to realize that correlations are with groups of patients overall, and may not fully reflect outcomes in individual patients.

**Testing at Diagnosis**

Table 7 summarizes the typical testing required at the time of diagnosis (baseline testing).

**Step 3: Initial treatment options.**

Deciding that treatment is necessary is the most important initial decision. As already emphasized, baseline testing, staging, and prognostic classification are essential. Treatment is recommended for active or symptomatic myeloma. The urgency of treatment depends upon the exact problems faced by an individual patient.

**Initial or Frontline Therapy**

It is important for patients to set aside plenty of time to discuss the options with their hematologist or hematologist/oncologist. In addition to the baseline test results, one must consider:

**Important Baseline Questions**

- **Day-to-day functioning:** Will treatment affect the ability to perform daily activities?
- **Work:** Will any changes or interruptions be required?
- **Age:** Is this a factor in treatment selection and expected outcomes?
- **Treatment side effects:** How significant will these be?
- **Other medical issues:** Will they affect treatment choices and tolerance to treatment?
- **Transplant:** Is high-dose chemotherapy with transplant recommended?
- **Speed of response:** How rapidly will the treatment work and how will that be assessed?
- **Initial and later decisions:** How much needs to be decided on Day 1?

It is best to keep the door open for stem cell transplantation if you feel it can be a future option for you. In general, patients who are younger than 65 years are considered candidates for stem cell transplant. In the United States, Medicare will cover a single autologous stem cell transplant for eligible patients up to the age of 77 years. Eligibility for stem cell transplant must be evaluated on an individual basis, taking into account health status, other illnesses, and treatment history.

Although frontline (first therapy after diagnosis) clinical trials are available, you have to be completely comfortable that you might be randomly assigned to one treatment versus another. You may become “locked in” to future randomization and treatments. Make sure you understand the full scope of the protocol.

**Key point:** If one treatment does not work, this does not mean that another treatment cannot work extremely well and give an excellent remission.
Step 4: Supportive care and how to get it.

Treatments are available to alleviate the physical and emotional impact of the disease.

Early use of supportive care measures is just as important as initiating frontline therapy.

Beyond the management of specific symptoms, a whole range of supportive measures is critically important:

- **Physical activity** – Patients should check with their physicians to clarify if full physical activity is feasible or if adjustments need to be made because of bone disease and/or particular areas of bone damage. Usually, some physical activity such as planned walking or swimming, flexibility and strengthening exercises, and/or a personalized yoga program, can be set up.

- **Diet** – No specific diet has been developed for myeloma patients. This is an area of ongoing research. In general, “healthy diet” recommendations from other disease settings such as cardiac disease and cancer in general (e.g., breast cancer) can be utilized. Caution should be used in two areas:
  - **Vitamin C** – High doses (i.e., >1000 mg/day) may be counter-productive in myeloma and increase the risk of kidney damage.
  - **Herbal and vitamin supplements** – Talk to your doctor or oncology center pharmacist about using supplements at the same time as chemotherapy or other drug treatment. Drug interactions can create medical problems. Most pharmacies have systems that identify potential interactions with supplements in addition to medications.

- **Mental health** – Your mental health is critical as you move forward with planned treatment. Make sure you are comfortable with the treatment planned. Schedule an appointment with a mental health professional if you believe that you might be depressed, or if others are concerned that you might be depressed.

- **Regular sleep** – This is very important for your immune system.

- **Make adjustments** – As much as possible, reduce or eliminate stress in job, family, or social situations. Avoid contact with school-age children, avoid crowds as much as possible, and wash hands frequently; your immune system is compromised both by the disease and the treatments. Management of the myeloma is the top priority until remission and/or a stable situation has been achieved.

### TABLE 8: Goals of Myeloma Treatment

<table>
<thead>
<tr>
<th>TYPE OF TREATMENT</th>
<th>OBJECTIVE</th>
<th>EXAMPLES</th>
<th>TIME TO DECIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stabilizing</td>
<td>Countering the life-threatening disruptions to body chemistry and the immune system</td>
<td>• Plasmapheresis to thin the blood and avoid stroke &lt;br&gt;• Hemodialysis when kidney function is impaired &lt;br&gt;• Drugs to reduce hypercalcemia (may include chemotherapy)</td>
<td>Hours to Days</td>
</tr>
<tr>
<td>Palliative</td>
<td>Relieving discomfort and increasing the patient’s ability to function</td>
<td>• Radiation to stop bone destruction &lt;br&gt;• Red cell transfusion or erythropoietin to relieve anemia &lt;br&gt;• Orthopedic surgery to repair and/or strengthen bone</td>
<td>Days to Months</td>
</tr>
<tr>
<td>Remission-Inducing</td>
<td>Improving symptoms, slowing or arresting the course of the disease</td>
<td>• Therapy to kill malignant cells throughout the body &lt;br&gt;• Radiation to kill malignant cells at a tumor site</td>
<td>Weeks to Months</td>
</tr>
<tr>
<td>Curative</td>
<td>Permanent remission*</td>
<td>• Bone marrow transplants as a means of delivering high-dose chemotherapy</td>
<td>Weeks to Months</td>
</tr>
</tbody>
</table>

* Cure means permanent eradication of myeloma, which is rarely documented. The term “functional cure” has been used to describe complete remissions which last for over 4 years. Complete response (including at the molecular level) can be followed by relapse, so long follow-up is required.
If Frontline Therapy is Not Working

There are numerous treatment options beyond the scope of this introductory handbook. Emerging new therapies are increasingly available and can provide major benefit.

Please visit the IMF website at myeloma.org for more information and regular updates, or call the IMF at 800-452-CURE (2873).

Questions to Ask Your Doctor

Treatment decisions are critically important to the survival and quality of life of the myeloma patient. To make an informed decision, the patient needs to have the facts. Some patients want to discuss all aspects of their situation, treatment, and prognosis. Others just want to know what to do next. Most doctors are sensitive to this and will vary their approach based on what they perceive to be the patient’s wishes. We encourage patients to be explicit about how deeply they want to get into the details of the treatment decision. And, no matter how comfortable the patient feels with a doctor, it is good practice to get a second opinion with a myeloma specialist before proceeding with treatment.

1. Get a complete description of the treatment program:
   - What exactly is the treatment?
   - What are the objectives of the treatment?
   - Over what period will the treatment be given?
   - What is involved? How often must the patient visit a medical facility? Is hospitalization required or a probability? What is the likely impact on the patient’s ability to function (i.e., work and play)? How do people feel before, during, and after treatment? How do they look? What are typical recovery time frames?
   - What follow-up or maintenance programs are required?
   - What will the treatment program cost? Will it be covered by health insurance?

2. How well has this treatment worked for others in similar situations? Effectiveness is measured in many different ways:
   - How much experience is there with the treatment? How many patients have received it? How long have those patients been followed after the treatment?
   - What are the odds of achieving a complete or partial remission? Which factors suggest better or worse odds?
   - How long have the patients’ remissions lasted? Which factors correlate with long or short remissions?
   - What would be the options in the event of a relapse? (These options may change in the interim.)
   - What are reasonable expectations for relieving symptoms such as bone pain, pathological fractures, anemia, fatigue, and hypercalcemia? What are the factors that predict how well these treatments will work for symptoms?
   - How long have people who have received the treatment survived? For newer treatments, how many of the original group of patients are still alive?

3. Like most cancer treatments, myeloma treatments generally use strong drugs and other measures aimed at destroying malignant cells and/or rebalancing body chemistry. Typically, there are side effects. Some manifest themselves during treatment. Others may show up well after the treatment is completed.
   - What side effects have been observed in patients receiving the treatment? When do they typically occur? In what percentage of patients do they occur? How serious are the side effects? Are they life threatening? Are they painful? Are they permanent? How long do they last?
   - Are there treatments for the side effects? Do the treatments for the side effects have side effects?

4. There are always alternatives. You need to ask all of these questions for each of the alternatives:
   - What are the alternatives to the recommended treatment?
   - What are the relative pros and cons of the alternatives?
   - What are the pros and cons of the alternative treatments vs. no treatment?

(text continues on page 17)
### TABLE 9A: Frontline Treatment Options – Transplant Eligible

<table>
<thead>
<tr>
<th>FRONTLINE THERAPY</th>
<th>COMMENTS</th>
<th>ADVANTAGES</th>
<th>DISADVANTAGES</th>
</tr>
</thead>
</table>
| **Velcade®** (bortezomib) | • Excellent and approved option in frontline  
• Usually used with dexamethasone | • Shows remarkable benefit  
• Many combinations available  
• Preferred in cases of renal compromise/abnormal genetic features | • Produces neuropathy that is partially or completely reversible in this setting  
• With subcutaneous use, the likelihood of neuropathy is significantly reduced |
| **Velcade** with dexamethasone | • Simplest Velcade option in frontline therapy | • Excellent response rates  
• New gold standard for frontline induction | • Intravenous or subcutaneous  
• Potential for side effects: peripheral neuropathy |
| **VTD** (Velcade/thalidomide/dexamethasone) | • Highly effective combination  
• Efficacy and side effects need physician discussion | • Very high response rate in phase III trial  
• Excellent outcomes post-transplant | • Intravenous combination  
• Potential for side effects: peripheral neuropathy |
| **More Complex Velcade Combinations** with Revlimid® (lenalidomide), Doxil® (doxorubicin), Cytoxan® (cyclophosphamide), or other agents | • Many highly effective combinations  
• Careful physician discussion required regarding combined agents vs. sequential use of agents over time | • Excellent response rates  
• Some combinations allow steroid-free treatment | • Intravenous combinations  
• Possible increased toxicities |
| **Dexamethasone plus Thalidomide** | • Value and side effects now compared to Rd (see below) | • An oral approach producing remission in 70% of patients | • Neuropathy and deep vein thrombosis (blood clots) are potential concerns |
| **R or Rd (RevloDex)** (Revlimid® alone or Revlimid® with low-dose dexamethasone) | • Very effective alternative to Thal/Dex  
• Often preferred by both physicians and patients | • Excellent response rates  
• Oral  
• Generally well-tolerated and causes far less neuropathy than thalidomide | • Revlimid alone can result in less effective response  
• Risk of blood clot problems with Rev/dex combination; requires aspirin or another blood thinner  
• Possible reduced stem cell harvest |
| **Dexamethasone** alone | • A simple option for early disease management  
• Pulse dexamethasone alone provides a substantial percentage of the benefit of the full VAD | | • Dexamethasone on an intensive schedule can be poorly tolerated |
| **VAD** (Vincristine/Adriamycin/Dexamethasone) | • Prior to novel agents was induction of choice  
• Now used as a “back-up” | • Produces remission in 70% of patients  
• Doesn’t damage normal stem cells  
• Can be basis for stem cell transplant | • Needs central line catheter for IV administration. The catheter can trigger infection and blood clot complications  
• Vincristine can cause nerve damage  
• New options are available that are more effective and less toxic |

* Can be used with or without plan for harvest and transplant.  
Further details about treatment options are available in other IMF publications.  
To order these, please contact the IMF at 800-452-2873 or visit our website at myeloma.org.
### TABLE 9B: Additional Frontline Treatment Options Table – Transplant Ineligible

<table>
<thead>
<tr>
<th>FRONTLINE THERAPY</th>
<th>ADVANTAGES</th>
<th>DISADVANTAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP</strong> (Melphalan + Prednisone)</td>
<td>• Taken by mouth</td>
<td>• Can cause bone marrow stem cell damage and therefore reduce chances of successful stem cell transplant</td>
</tr>
<tr>
<td></td>
<td>• Well tolerated</td>
<td>• Full benefit occurs slowly over several months</td>
</tr>
<tr>
<td></td>
<td>• Produces excellent remissions in about 60% of patients</td>
<td>• Not ideal if prompt response required and/or if stem cell transplant</td>
</tr>
<tr>
<td></td>
<td>• Physicians very familiar with protocol</td>
<td></td>
</tr>
<tr>
<td><strong>Dexamethasone plus Melphalan</strong></td>
<td>• This combination produces more rapid benefit than MP</td>
<td>• The use of melphalan up-front damages stem cells</td>
</tr>
<tr>
<td><strong>MPT</strong> (MP + thalidomide)</td>
<td>• Taken by mouth</td>
<td>• Dexamethasone can be difficult for older patients</td>
</tr>
<tr>
<td></td>
<td>• Well tolerated</td>
<td>(if used, consider 1 day/week)</td>
</tr>
<tr>
<td></td>
<td>• Higher remission rate than MP</td>
<td></td>
</tr>
<tr>
<td><strong>VMP</strong> (Velcade + MP)</td>
<td>• Generally well tolerated</td>
<td>• Same as for MP</td>
</tr>
<tr>
<td></td>
<td>• No blood clot risk</td>
<td>• Thalidomide has risks of neuropathy and/or blood clot problems (DVT)</td>
</tr>
<tr>
<td></td>
<td>• Higher remission rate than MP</td>
<td></td>
</tr>
<tr>
<td><strong>MPR</strong> (MP + Revlimid)</td>
<td>• Taken by mouth</td>
<td>• Velcade is intravenous (IV) or subcutaneous (SQ)</td>
</tr>
<tr>
<td></td>
<td>• Well tolerated</td>
<td>• Significant risk of neuropathy</td>
</tr>
<tr>
<td></td>
<td>• Higher remission rate than MP</td>
<td></td>
</tr>
<tr>
<td><strong>A variety of other therapies are sometimes used</strong></td>
<td>• Combinations provide a more aggressive approach, if deemed necessary</td>
<td>• More side effects than simpler regimens</td>
</tr>
<tr>
<td></td>
<td>such as cyclophosphamide and Etoposide® (VP-16).</td>
<td>• No added longer-term benefit</td>
</tr>
<tr>
<td></td>
<td>Potential combinations include:</td>
<td>• Symptoms of active disease may be controlled more rapidly and quality of</td>
</tr>
<tr>
<td></td>
<td>• VBMCP (M2 protocol)</td>
<td>first remission may be better</td>
</tr>
<tr>
<td></td>
<td>• VMCP/VBAP (SWOG protocol)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ABCM (UK MRC protocol)</td>
<td></td>
</tr>
</tbody>
</table>

Further details about treatment options are available in other IMF publications. To order these, please contact the IMF at 800-452-2873 or visit our website at myeloma.org.
**TABLE 10: Supportive Care**

<table>
<thead>
<tr>
<th>SYMPTOM</th>
<th>TREATMENT</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| Fatigue and weakness due to anemia     | • Blood transfusion (packed red blood cells: leukoreduced, virus screened) if anemia severe  
• Erythropoietin if anemia mild to moderate and induced by therapy | The treatments are simple, usually highly beneficial, and improve feelings of well-being.  |
| Bone Pain                              | • Bisphosphonate (e.g., Aredia® 90 mg IV over 2-4 hrs monthly; Zometa® 4 mg IV over 15-45 minutes monthly)  
• Pain medication as needed (e.g., Tylenol®, oral morphine derivatives, Fentanyl® “Pain Patch”) | Relief of bone pain is important in itself and improves physical activity, which in turn promotes bone strength and healing and improves emotional well-being. Potential damage to kidneys and jaws, though rare, can result from chronic bisphosphonate therapy. Awareness is the key to prevention.  |
| Fever and/or evidence of infection     | • Appropriate antibiotics  
• Neupogen® if necessary to boost low white blood cell count  
• Intravenous gamma globulin for severe infections  
• Tests as needed to diagnose the exact type of infection should be performed (except for dangerous biopsies/cultures) | Although antibiotics should be selected and used with care, it is extremely important that infections be brought under control promptly. Having an antibiotic on hand for emergency use (especially if traveling) is recommended.  |
| Gastrointestinal side effects          | • Appropriate medications to treat nausea, vomiting, constipation, or diarrhea  
• Maintain adequate fluid intake and nutrition | Discuss symptoms with healthcare providers; severe symptoms may require hospitalization.  |
| Blood clots and thromboembolic events  | • Clotting events are medical emergencies; treatment based on event and patient risk factors  
• Aspirin or anti-clotting medications may be prescribed | Risk may be reduced by exercise, weight loss, not smoking.  |
| Peripheral neuropathy                  | • Pain medications  
• Adjustment of dose, schedule, and/or route of administration  
• Physical therapy, vitamin and other supplements | Discuss symptoms with healthcare providers. Early intervention can prevent permanent damage and allow continued treatment. Do not adjust doses on your own. Do not take supplements without discussing with doctor.  |
| Steroid side effects                   | • Take with food early in the morning  
• Be aware of signs and symptoms of infection, changes in blood sugar  
• Medications to prevent shingles and yeast infections | Report side effects and symptoms to healthcare providers. Do not stop or adjust doses on your own.  |

*Patient education sheets on preventing blood clots and thromboembolic events, managing steroid-associated side effects, managing myelosuppression, preventing peripheral neuropathy, and managing gastrointestinal side effects are available from the IMF. To order these, please contact the IMF or visit our website at myeloma.org*
Because the disease is rare, there are a limited number of practitioners and centers specializing in myeloma. It is very common for a myeloma patient to seek a second opinion from a specialist at a research center while continuing to rely on a local referring physician to administer and monitor treatment.

Making good decisions about treatment requires resourcefulness, careful questioning, serious thought, and courage. But most of all, it requires that the patient and those who help support him or her take charge of the process. Because there is no known cure, because there are no guarantees, because every individual is different, the ultimate decision depends on the preferences and priorities of the patient.

**Terms and Definitions**

**Accrual**: The process of enrolling patients in a clinical research study (trial), or the number of patients already enrolled in a trial or anticipated to enroll in a trial.

**Acute**: A sudden onset of symptoms or disease.

**Albumin**: Simple water-soluble proteins that are found in blood serum and many other animal and plant tissues.

**Alkylating agent**: A chemotherapeutic agent such as melphalan or cyclophosphamide. Alkylating refers to the way in which these agents cross-link the DNA of myeloma cells and block cell division.

**Allogeneic**: See “Transplantation.”

**Amyloidosis**: A condition in which myeloma light chains (Bence Jones proteins) are deposited in tissues and organs throughout the body. This occurs more commonly with lambda versus kappa Bence Jones proteins. In patients with amyloidosis, the light chain proteins bind to certain tissues such as heart, nerves, and kidney rather than being excreted out of the body through the kidneys.

**Analgesic**: Any drug that relieves pain. Aspirin and acetaminophen are mild analgesics.

**Analog**: A chemical compound that is structurally similar to another but differs slightly in composition.

**Anemia**: A decrease in the hemoglobin, usually below 10 g/dL, with over 13-14 g/dL being normal. Myeloma in the bone marrow blocks red blood cell production, causing shortness of breath, weakness, and tiredness.

**Anesthesia**: Loss of feeling or awareness. Local anesthesia causes loss of feeling in a part of the body. General anesthesia puts the person to sleep.

**Angiogenesis**: Blood vessel formation, which usually accompanies the growth of malignant tissue, including myeloma.

**Angiogenesis inhibitors**: Compounds that attempt to cut off the blood supply to tumors.

**Antibiotics**: Drugs used to treat infection.

**Antibody**: A protein produced by certain white blood cells (plasma cells) to fight infection and disease in the form of antigens such as bacteria, viruses, toxins, or tumors. Each antibody can bind only to a specific antigen. The purpose of this binding is to help destroy the antigen.

Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies disable antigens directly. Others make the antigen more vulnerable to destruction by other white blood cells.

**Anti-emetic agent**: A drug that prevents or controls nausea and vomiting.

**Antifungal agent**: A drug used to treat fungal infections.

**Antigen**: Any foreign substance (such as a bacteria, virus, toxin or tumor) that, when introduced into or arising in the body, causes the immune system to produce natural antibodies.

**Antineoplastic agent**: A drug that prevents, kills, or blocks the growth and spread of cancer cells.

**Appendicular skeleton**: The long bones (i.e., arms and legs), which are attached to spine, chest and pelvis.

**Apoptosis**: A normal cellular process involving a genetically programmed series of events leading to the death of a cell.
**Aspiration**: The process of removing fluid or tissue, or both, from a specific area.

**Asymptomatic myeloma**: Myeloma that presents no signs or symptoms of disease. Also called indolent, smoldering, or early-stage myeloma.

**Axial skeleton**: The skull, spine, and pelvic region of the skeleton.

**B cells**: White blood cells that develop into plasma cells in the bone marrow and are the source of antibodies. Also known as B lymphocytes.

**Basophil**: A type of white blood cell. Basophils are granulocytes.

**Bence Jones**: A myeloma monoclonal protein present in urine. The amount of Bence Jones protein is expressed in terms of grams per 24 hours. Normally a very small amount of protein (<0.1 g/24 h) can be present in the urine, but this is albumin rather than Bence Jones protein. The presence of any Bence Jones protein is abnormal.

**Benign**: Not cancerous; does not invade nearby tissue or spread to other parts of the body. MGUS is a benign condition.

**Beta 2 microglobulin (β2M)**: A small protein found in the blood. High levels occur in patients with active myeloma. Low or normal levels occur in patients with early myeloma and/or inactive disease. Approximately 10% of patients have myeloma that does not produce β2M. At the time of relapse, β2M can increase before there is any change in the myeloma protein level. Factors such as viral infection can sometimes produce elevated serum β2M levels.

**Biopsy**: The removal of a sample of tissue for microscopic examination to aid in diagnosis.

**Bisphosphonate**: A type of drug that binds to the surface of bone where it is being resorbed (or destroyed) and protects against osteoclast activity.

**Blood cells**: Minute structures produced in the bone marrow; they include red blood cells, white blood cells, and platelets.

**Blood count**: The number of red blood cells, white blood cells, and platelets in a sample of blood.

**Bone marrow**: The soft, spongy tissue in the center of bones that produces white blood cells, red blood cells, and platelets.

**Bone marrow aspiration**: The removal, by a needle, of a sample of fluid and cells from the bone marrow for examination under a microscope.

**Bone marrow biopsy**: The removal, by a needle, of a sample of tissue from the bone. The cells are checked to see whether they are cancerous. If cancerous plasma cells are found, the pathologist estimates how much of the bone marrow is affected. Bone marrow biopsy is usually done at the same time as bone marrow aspiration.

**Bone remodeling**: The normal coordination (coupling) between osteoclast cells (which resorb or destroy bone) and osteoblast cells (which create new bone matrix) to maintain a balanced state of bone production and destruction.

**BUN (Blood Urea Nitrogen)**: A measure of the urea level in the blood. Urea is cleared by the kidney. BUN is a laboratory blood test to assess how well the kidney is functioning. Diseases such as myeloma which compromise kidney function frequently lead to increased levels of BUN.

**Calcium**: A mineral found mainly in the hard part of bone matrix or hydroxyapatite.

**Cancer**: A term for diseases in which malignant cells divide without control. Cancer cells can invade nearby tissues and spread through the bloodstream and lymphatic system to other parts of the body.

**Carcinogen**: Any substance or agent that produces or stimulates cancer growth.

**CAT or CT [Computerized (Axial) Tomography scan]**: A test using computerized X-rays to create three-dimensional images of organs and structures inside the body, used to detect small areas of bone damage or soft tissue involvement.

**Catheter**: A tube that is placed in a blood vessel to provide a pathway for drugs or nutrients. A Central Venous Catheter is special tubing that is surgically inserted into a large vein near the heart and exits from the chest or abdomen. The catheter allows
medications, fluids, or blood products to be given and blood samples to be taken.

**Cell:** The basic unit of any living organism.

**Cell differentiation:** The process during which young, immature (unspecialized) cells take on individual characteristics and reach their mature (specialized) form and function.

**Cell proliferation:** An increase in the number of cells as a result of cell growth and cell division.

**Chemotherapy:** The treatment of cancer with drugs that kill all rapidly dividing cells.

- *Combination chemotherapy* – The use of more than one drug given in a chemotherapy regimen during cancer treatment.

**Chromosome:** A strand of DNA and proteins in the nucleus of a cell. Chromosomes carry genes and function in the transmission of genetic information. Normally, human cells contain 46 chromosomes.

**Chronic:** Persisting over a long period of time.

**Clinical:** Involving direct observation of a patient.

**Clinical trial:** A research study of new treatment that involves patients. Each study is designed to find better ways to prevent, detect, diagnose, or treat cancer and to answer scientific questions.

- *Control group* – The arm of a randomized clinical trial that gets the standard treatment.

- *End Point* – What a clinical trial is trying to measure or find out; the goal of the trial. Typical end points include measurements of toxicity, response rate, and survival.

- *Experimental group* – The arm of a randomized trial that gets the new treatment.

- *Randomized clinical trial* – A research study in which subjects are randomly assigned to receive a particular treatment.

- *Phase I trial* – A trial designed to determine the MTD (maximum tolerated dose) of a new drug or a new combination of drugs that has never been tried in humans. It is usually the first human testing of a new treatment, although in phase I trials of combination therapies, the individual elements may already have been well tested. Patients in phase I trials must have advanced cancer that is refractory to any standard treatment. In a typical phase I trial, successive groups (“cohorts”) of 3 to 6 patients are given the treatment. All patients in a cohort get the same dose. The first cohort typically gets a very low dose, and the dose is raised in each subsequent cohort until a set number of patients experience dose-limiting toxicity (DLT). The dose level used for the previous cohort is then taken to be the MTD. This dose is then used in a phase II trial.

- *Phase II trial* – A trial designed to determine the response rate of a new therapy that has already been tested in phase I trials. Typically, 14 to 50 patients with one type of cancer are treated to see how many have a response. Patients are usually required to have advanced cancer that is refractory to any standard treatment, and in addition, they must have measurable disease. If results from a phase II trial are promising enough, the treatment may then be tested in a phase III trial. If the results are obviously much better than the standard treatment, then it may not be necessary to do a phase III trial, and the treatment may become standard based on phase II trial results.

- *Phase III trial* – A trial designed to compare two or more treatments for a given type and stage of cancer. The end point of a phase III trial is usually survival or disease-free survival. Phase III trials are usually randomized, so patients don’t choose which treatment they receive. A typical phase III trial has 50 to thousands of patients. Some phase III trials compare a new treatment that has had good results in phase II trials with an older, well known, standard treatment. Other phase III trials compare treatments that are already in common use. Some treatments in phase III trials may be available outside the clinical trial setting.

**Creatinine:** A small chemical compound normally excreted by the kidneys. If the kidneys are damaged, the serum level of creatinine builds up, resulting in an elevated serum creatinine. The serum creatinine test is used to measure kidney function.

**Cyst:** An accumulation of fluid or semi-solid material within a sac.

**Cytokine:** A substance secreted by cells of the immune system that stimulates growth/activity in a particular type of cell. Cytokines are produced locally (i.e., in the bone marrow) and circulate in the bloodstream.
**DEXA (Dual Photon X-ray Absorptiometry) study:** Measures the amount of bone loss; the best measure of bone density.

**Dexamethasone:** A powerful corticosteroid given alone or with other drugs.

**Diagnosis:** The process of identifying a disease by its signs and symptoms.

**Dialysis:** When a patient’s kidneys are unable to filter blood, the blood is cleaned by passing it through a dialysis machine.

**Disease-free survival:** The length of time the patient survives without any detectable cancer.

**DLT (Dose-Limiting Toxicity):** Side effects severe enough to prevent giving more of the treatment.

**DNA:** The substance of heredity; a large molecule that carries the genetic information that cells need to replicate and to produce proteins.

**Drug resistance:** The result of cells’ ability to resist the effects of a specific drug.

**Edema:** Swelling; an abnormal accumulation of fluid in part of the body.

**Efficacy:** The power to produce an effect; in cancer research ‘efficacy’ refers to whether the treatment is effective.

**Electrophoresis:** A laboratory test in which a patient’s serum (blood) or urine molecules are subjected to separation according to their size and electrical charge. For myeloma patients, electrophoresis of the blood or urine allows both the calculation of the amount of myeloma protein (M-protein) as well as the identification of the specific M-spike characteristic for each patient. Electrophoresis is used as a tool both for diagnosis and for monitoring.

**Enzyme:** A substance that affects the rate at which chemical changes take place in the body.

**Erythrocytes:** Red blood cells (RBCs). RBCs carry oxygen to body cells and carbon dioxide away from body cells.

**Erythropoietin:** A hormone produced by the kidneys. Myeloma patients with damaged kidneys don’t produce enough erythropoietin and can become anemic. Injections with synthetic erythropoietin can be helpful. Blood transfusion is another alternative, especially in an emergency.

Synthetic erythropoietin is used as a supportive therapy during anti-myeloma treatment to avoid anemia.

**Free light chains:** A portion of the monoclonal protein of light molecular weight that can be measured in a sensitive assay, the Freelite test.

**Gene:** A specific sequence of DNA or RNA; the biological unit of heredity located in a specific place on a chromosome and found in all cells in the body. When genes are missing or damaged, cancer may occur.

**Gene therapy:** Treatment that alters genes. Using genes to stimulate the immune system. In studies of gene therapy for cancer, researchers are trying to improve the body’s natural ability to fight the disease and to make the tumor more sensitive to other kinds of therapy. Treatment focuses on replacing damaged or missing genes with healthy copies.

**Genetic:** Inherited; having to do with information that is passed from parents to children through DNA in the genes.

**Graft-versus-host disease (GVHD):** A reaction of donated bone marrow against the recipient’s own tissue.

**Granulocyte:** A type of white blood cell that kills bacteria. Neutrophils, eosinophils, and basophils are granulocytes.

**Hematocrit (Hct):** The percentage of red blood cells in the blood. A low hematocrit measurement indicates anemia.

**Hematologist:** A doctor who specializes in the problems of blood and bone marrow.

**Hemoglobin:** A protein in red blood cells that carries oxygen in the blood.

**Herpes simplex:** A common virus, it causes sores often seen around the mouth, commonly called cold sores.
**Herpes zoster**: A virus that settles around certain nerves in patients who have previously had a chickenpox (varicella) infection, causing blisters, swelling, and pain. This condition is also called shingles.

**Hormones**: Chemicals produced by various glands of the body that regulate the actions of certain cells or organs.

**Human leukocyte antigen (HLA) test**: A blood test used to match a blood or bone marrow donor to a recipient for transfusion or transplant.

**Hypercalcemia**: A higher-than-normal level of calcium in the blood. This condition can cause a number of symptoms, including loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Common in myeloma patients and usually resulting from bone destruction with release of calcium into the bloodstream. Often associated with reduced kidney function since calcium can be toxic to the kidneys. For this reason, hypercalcemia is usually treated on an emergency basis using IV fluids combined with drugs to reduce bone destruction along with direct treatment for the myeloma.

**IgG, IgA**: The two most common types of myeloma. The G and the A refer to the type of protein produced by the myeloma cells. The myeloma protein, which is an immunoglobulin, consists of two heavy chains, (for example of a G type) combined with two light chains, which are either kappa or lambda. Therefore, the two most common subtypes of myeloma have identical heavy chains (i.e. IgG kappa and IgG lambda). The terms heavy and light refer to the size or molecular weight of the protein, with the heavy chains being larger than the light chains. Since the light chains are smaller, they are more likely to leak out into the urine, resulting in urine Bence Jones protein.

**IgD, IgE**: Two types of myeloma that occur less frequently.

**IgM**: Usually associated with Waldenström’s macroglobulemia. In rare cases can be a type of myeloma.

**Immune system**: The complex group of organs and cells that produces antibodies to defend the body against foreign substances such as bacteria, viruses, toxins, and cancers.

**Immunodeficiency**: A lowering of the body’s ability to fight off infection and disease.

**Immunofixation**: An immunologic test of the serum or urine used to identify proteins in the blood. For myeloma patients, it enables the doctor to identify the M-protein type (IgG, IgA, kappa, or lambda). The most sensitive routine immunostaining technique, it identifies the exact heavy and light chain type of M-protein.

**Immunoglobulin (Ig)**: A protein produced by plasma cells; an essential part of the body’s immune system. Immunoglobulins attach to foreign substances (antigens) and assist in destroying them. The classes of immunoglobulins are IgA, IgG, IgM, IgD, and IgE.

**Immunosuppression**: Weakening of the immune system that causes a lowered ability to fight infection and disease. Immunosuppression may be deliberate, such as in preparation for bone marrow transplantation to prevent rejection by the host of the donor tissue, or incidental, such as often results from chemotherapy for the treatment of cancer.

**Immunotherapy**: Treatment that stimulates the body’s natural defenses to fight cancer. Also called biological therapy.

**Incidence**: The number of new cases of a disease diagnosed each year.

**Induction therapy**: The initial treatment used in an effort to achieve remission in a newly diagnosed myeloma patient.

**Informed consent**: The process requiring a doctor to give a patient enough information about a proposed procedure for the patient to make an informed decision about whether or not to undergo it. The doctor must, in addition to explaining all procedures, address the issues of risks, benefits, alternatives, and potential costs.

**Infusion**: Delivering fluids or medications into the bloodstream over a period of time.

**Infusion pump**: A device that delivers measured amounts of fluids or medications into the bloodstream over a period of time.

**Inhibit**: To stop something, to hold in check.
**Injection**: Pushing a medication into the body with the use of a syringe and needle.

**Interferon**: A naturally produced hormone (cytokine) released by the body in response to infection or disease which stimulates the growth of certain disease-fighting blood cells in the immune system. Interferon can be artificially produced by genetic engineering techniques and used as a form of immunotherapy, primarily in the maintenance (plateau) phase to block any regrowth of myeloma and thus delay or prevent relapse.

**Interleukin**: A naturally produced chemical released by the body or a substance used in biological therapy. Interleukins stimulate the growth and activities of certain kinds of white blood cells. Interleukin-2 (IL-2) is a type of biological response modifier that stimulates the growth of certain blood cells in the immune system that can fight some types of cancer. Interleukin-6 (IL-6) is a cytokine that is a potent stimulus to osteoclast and plasma cell activities.

**LDH**: Lactate dehydrogenase, an enzyme that may be used to monitor myeloma activity.

**Lesion**: An area of abnormal tissue change. A lump or abscess that may be caused by injury or disease, such as cancer. In myeloma, “lesion” can refer to a plasmacytoma or a hole in the bone.

**Leukocytes**: Cells that help the body fight infections and other diseases. Also called white blood cells (WBCs).

**Leukopenia**: A low number of white blood cells.

**Lymphocytes**: White blood cells that fight infection and disease.

**Lytic lesions**: The damaged area of a bone that shows up as a dark spot on an X-ray when enough of the healthy bone in any one area is eaten away. Lytic lesions look like holes in the bone and are evidence that the bone is being weakened.

**M proteins (M spike)**: Antibodies or parts of antibodies found in unusually large amounts in the blood or urine of multiple myeloma patients. M spike refers to the sharp pattern that occurs on protein electrophoresis when an M protein is present. Synonymous with monoclonal protein and myeloma protein. (see “monoclonal” below)

**Maintenance therapy**: Drugs given to patients in remission to delay or prevent a relapse.

**Malignant**: Cancerous; capable of invading nearby tissue and spreading to other parts of the body.

**MDR (Multi Drug Resistance)**: A resistance to standard treatment, typically associated with resistance to Adriamycin and vincristine, both chemotherapy drugs. The resistance is caused by a buildup of the p-glycoprotein in the outer cell membrane of the myeloma cells. This results in drugs being kicked back out of the myeloma cell instead of building up and eventually killing that cell.

**Melanoma**: A cancer of the pigment-forming cells of the skin or the retina of the eye. Not associated with myeloma despite the similar-sounding name.

**Metastasize**: To spread from one part of the body to another. When cancer cells metastasize and form secondary tumors, the cells in the metastatic tumor are like those in the original (primary) tumor. This term is commonly used to describe a disease process in solid tumors (e.g., breast, prostate) and not in myeloma, which is a blood-related cancer.

**MGUS (Monoclonal Gammapathy of Undeter-mined Significance)**: A benign condition in which the M protein is present but there is no underlying disease.

**Molecule**: The smallest particle of a substance that retains all the properties of the substance and is composed of one or more atoms.

**Monoclonal**: A clone or duplicate of a single cell. Myeloma develops from a single malignant plasma cell (monoclonal). The type of myeloma protein produced is also monoclonal; a single form rather than many forms (polyclonal). The important practical aspect of a monoclonal protein is that it shows up as a sharp spike (M spike) in the serum electrophoresis test.

**Monoclonal antibodies**: Artificially manufactured antibodies specifically designed to find and bind to cancer cells for diagnostic or treatment purposes. They can be used alone, or they can be used to deliver drugs, toxins, or radioactive material directly to tumor cells.
Monocyte: A type of white blood cell.

MRI (Magnetic Resonance Imaging): A diagnostic test that uses magnetic energy, rather than X-ray energy, to produce detailed two- or three-dimensional images of organs and structures inside the body. Gives very fine resolution of soft tissues, especially encroachments on the spinal cord, but is less accurate for bone lesions.

MTD (Maximum Tolerated Dose): The highest dose of a treatment that most people can safely withstand.

Myelodysplastic syndrome: A condition in which the bone marrow does not function normally and does not produce enough blood cells. This condition may progress and become acute leukemia.

Myeloid: Referring to myelocytes, a type of white blood cell. Also called myelogenous. Multiple myeloma is a non-myeloid cancer.

Myelosuppression: A decrease in the production of red blood cells, platelets, and some white blood cells by the bone marrow.

Neoplasia: Abnormal new growth of cells.

Neoplasm: A new growth of tissue or cells; a tumor that can be referred to as benign or malignant.

Neutropenia: A reduced level of neutrophils. Cytotoxic chemotherapy has a tendency to induce neutropenia. In contrast, lymphocytes which are more important in viral infections, tend not to be affected by cytotoxic treatment. Neutropenia can be prevented or reduced using a synthetic hormone called G-CSF (e.g. Neupogen).

Neutrophil: A type of white blood cell necessary to combat bacterial infection.

Oncogene: A gene or DNA sequence that normally directs cell growth, but which can also promote or allow the uncontrolled growth of cancer if damaged (mutated) by an environmental exposure to carcinogens, or if damaged or missing because of an inherited defect. A gene that has the potential to cause a normal cell to become cancerous.


Osteoblast: The cell that produces osteoid, which becomes mineralized with calcium to form new hard bone.

Osteoclast: A cell found in the bone marrow at the junction between the bone marrow and the bone that resorbs or breaks down old bone. In myeloma, the osteoclasts are over-stimulated while osteoblast activity is blocked. The combination of accelerated bone resorption and blocked new bone formation results in lytic lesions.

Osteoid: The protein product which becomes mineralized with calcium to form hard bones.

Osteonecrosis of the jaw: A previously rare jaw problem now being observed in a small percentage of patients taking bisphosphonates. The condition produces pain, swelling, and bone damage around the tooth sockets in the jaws. There is bone necrosis or loss of bone which can lead to loose teeth, sharp edges of exposed bone, bone spurs, and the breaking loose of small bone spicules or dead bone. A case definition is ≥3 months with non-healing exposed bone. Symptoms may not be obvious at first, or may include pain, swelling, numbness or a “heavy jaw” feeling, or loosening of a tooth.

Osteoporosis: Reduction in bone density typically associated with old age. Diffuse involvement of bones with myeloma produces what looks like osteoporosis on X-ray and bone density measurement.

Palliative treatment: Aimed to improve the quality of life by relieving pain and symptoms of disease but not intended to alter its course.

Pathological fracture: A break in a bone usually caused by cancer or some disease condition. Occurs in myeloma-weakened bones, which can’t bear normal weight or stress.

Pathology: The study of disease by the examination of tissues and body fluids under the microscope. A doctor who specializes in pathology is called a pathologist.
**PET (Positron Emission Tomography) scan**: A diagnostic test that uses a sophisticated camera and computer to produce images of the body. PET scans show the difference between healthy and abnormally functioning tissues.

**Placebo**: An inert (inactive) substance often used in clinical trials for comparison with an experimental drug.

**Plasma**: The liquid part of the blood in which red blood cells, white blood cells, and platelets are suspended.

**Plasma cells**: Special white blood cells that produce antibodies. The malignant cell in myeloma. Normal plasma cells produce antibodies to fight infection. In myeloma, malignant plasma cells produce large amounts of abnormal antibodies that lack the capability to fight infection. The abnormal antibodies are the monoclonal protein, or M protein. Plasma cells also produce other chemicals that can cause organ and tissue damage (i.e., anemia, kidney damage, and nerve damage).

**Plasmacytoma**: A collection of plasma cells found in a single location rather than diffusely throughout the bone marrow, soft tissue, or bone.

**Plasmapheresis**: The process of removing certain proteins from the blood. Plasmapheresis can be used to remove high levels of monoclonal myeloma protein from the blood of multiple myeloma patients.

**Platelet**: One of the three major blood elements, others being the red blood cells and white blood cells. Platelets plug up breaks in the blood vessel walls and release substances that stimulate blood clot formation. Platelets are the major defense against bleeding. Also called thrombocytes.

**Port (implanted)**: A catheter connected to a quarter-sized disc that is surgically placed just below the skin in the chest or abdomen. The catheter is inserted into a large vein or artery directly into the bloodstream. Fluids, drugs, or blood products can be infused, and blood can be drawn through a needle that is stuck into the disc.

**Prognosis**: The projected outcome or course of a disease; the chance of recovery; the life expectancy.

**Progression-free survival**: The time period during which the patient survives and the cancer does not become worse. The improved survival of a patient that can be directly attributed to the treatment given for the myeloma. This term identifies myeloma patients who are in complete remission versus those who have had an episode of relapse or progression.

**Progressive disease**: Disease that is becoming worse, as documented by tests.

**Protocol**: A detailed plan of treatment including the dose and schedule of any drugs used.

**Precancerous**: A term used to describe a condition that may, or is likely to become, cancer.

**Radiation therapy**: Treatment with x-rays, gamma rays, or electrons to damage or kill malignant cells. The radiation may come from outside the body (external radiation) or from radioactive materials placed directly in the tumor (implant radiation).

**Radiologist**: A doctor who specializes in creating and interpreting images of areas inside the body. The images are produced with x-rays, sound waves, magnetic fields, or other types of energy.

**Recurrence**: The reappearance of a disease after a period of remission.

**Red blood cells (erythrocytes)**: Cells in the blood that contain hemoglobin and deliver oxygen to and take carbon dioxide from all parts of the body. Red cell production is stimulated by a hormone (erythropoietin) produced by the kidneys. Myeloma patients with damaged kidneys don't produce enough erythropoietin and can become anemic. Injections with synthetic erythropoietin can be helpful. Blood transfusion is another alternative, especially in an emergency. Synthetic erythropoietin is a supportive therapy used during anti-myeloma treatment to avoid anemia.

**Refractory**: Disease that is unresponsive to standard treatments.

**Regression**: The shrinkage of cancer growth.

**Relapse**: The reappearance of signs and symptoms of a disease after a period of improvement.
**Remission or response**: Complete or partial disappearance of the signs and symptoms of cancer. Remission and response are used interchangeably.

- **Complete Remission (CR)** – CR is the absence of myeloma protein from the serum and/or urine by standard testing; absence of myeloma cells from the bone marrow and/or other areas of myeloma involvement; clinical remission and improvement of other laboratory parameters to normal. CR is not the same thing as a cure.

- **Very Good Partial Remission (VGPR)** – VGPR is just less than CR, that is, when myeloma protein levels are reduced by ≥90%, but not gone.

- **Partial Remission (PR)** – PR is a level of response less than CR. In SWOG studies, it has meant >50% and <75% response. In other studies it has meant >50% response.

**RNA (ribonucleic acid)**: Any of various nucleic acids that are associated with the control of cellular chemical activities. RNA is one of the two nucleic acids found in all cells – the other is DNA (deoxyribonucleic acid). RNA transfers genetic information from DNA to proteins produced by the cell.

**Serum osteocalcin**: A protein produced and secreted by osteoblasts when they are making osteoid. A low level reflects active myeloma. A higher than normal level reflects more stable myeloma.

**Shingles**: See “Herpes zoster.”

**Side effects**: Problems that occur due to drugs used for disease treatment. Common side effects of cancer chemotherapy are fatigue, nausea, vomiting, decreased blood cell counts, hair loss, and mouth sores.

**Skeletal survey (metastatic survey)**: A series of plain X-rays of the skull, spine, ribs, pelvis, and long bones to look for lytic lesions and/or osteoporosis.

**Stable disease**: This describes patients who have some response to treatment but <50% reduction in myeloma protein levels. Stable disease is not necessarily bad or sub-optimal (as compared with CR or PR) provided the myeloma has stabilized and is not progressing. With slow-moving myeloma, stabilization can last for many years.

**Stage**: The extent of a cancer in the body.

**Staging**: Doing exams and tests to learn the extent of the cancer in the body.

**Stem cells**: The immature cells from which all blood cells develop. Normal stem cells give rise to normal blood components, including red cells, white cells, and platelets. Stem cells are normally located in the bone marrow and can be harvested for transplant.

**Steroid**: A type of hormone. Steroids are often given to patients along with one or more anticancer drugs and appear to help to control the effects of the disease on the body.

**Supportive care**: Treatment given to prevent, control, or relieve complications and side effects and to improve the patient’s comfort and quality of life.

**Systemic therapy**: Treatment using substances that travel through the bloodstream, reaching and affecting cancer cells all over the body.

**Thrombocytes**: See “Platelets.”

**Thrombocytopenia**: A low number of platelets in the blood. The normal level is 150,000-250,000. If the platelet count is less than 50,000, bleeding problems could occur. Major bleeding is usually associated with a reduction to less than 10,000.

**TNF (Tumor Necrosis Factor)**: A type of biological response modifier that can improve the body’s natural response to disease.

**Toxins**: Poisons produced by certain animals, plants, or bacteria.

**Transfusion**: The transfer of blood or blood products.

**Transplantation**: There are several different types of transplantation.

- **Bone marrow transplantation** – This term refers to the process of collecting stem cells from the bone marrow and infusing them into a patient. This term is used less frequently today in myeloma as stem cells are now collected from the peripheral or circulating blood.

- **Peripheral blood stem cell transplantation** – Doctors remove healthy stem cells from a patient’s circulating blood system (not from the bone marrow) and
store them before the patient receives high-dose chemotherapy to destroy the cancer cells. The stem cells are then returned to the patient, where they can produce new blood cells to replace cells destroyed by the treatment.

- **Allogeneic** – The infusion of bone marrow or stem cells from one individual (donor) to another (recipient). A patient receives bone marrow or stem cells from a compatible, though not genetically identical, donor.

- **Autologous** – A procedure in which stem cells are removed from a patient’s blood and then are given back to the patient following intensive treatment.

- **Matched unrelated donor transplants (MUDs)** – Refers to stem cell transplantation procedures in which the patient and the stem cells are genetically matched but are not from family members. This procedure is not recommended for myeloma patients because it carries an unacceptably high mortality rate.

- **Syngeneic** – The infusion of bone marrow or stem cells from one identical twin into another.

**Tumor**: An abnormal mass of tissue that results from excessive cell division. Tumors perform no useful body function. They may either be benign or malignant.

**Tumor marker**: A substance in blood or other body fluids that may suggest that a person has cancer.

**Vaccine**: A preparation of killed microorganisms, living attenuated organisms, or living fully virulent organisms that is administered to produce or artificially increase immunity to a particular disease.

**Virus**: A small living particle that can infect cells and change how the cells function. Infection with a virus can cause a person to develop symptoms.

The disease and symptoms that are caused depend on the type of virus and the type of cells that are infected.

**Waldenström’s macroglobulinemia**: A rare type of indolent lymphoma that affects plasma cells. Excessive amounts of IgM protein are produced. Not a type of myeloma.

**White blood cells (WBC)**: General term for a variety of cells responsible for fighting invading germs, infection, and allergy-causing agents. These cells begin their development in the bone marrow and then travel to other parts of the body. Specific white blood cells include neutrophils, granulocytes, lymphocytes, and monocytes.

**X-ray**: High-energy electromagnetic radiation used in low doses to diagnose diseases and in high doses to treat cancer.
About the International Myeloma Foundation

Founded in 1990, the International Myeloma Foundation (IMF) is the oldest and largest myeloma-specific charity in the world. With more than 230,000 members in 120 countries, the IMF serves myeloma patients, family members, and the medical community. The IMF provides a wide range of programs in the areas of Research, Education, Support, and Advocacy.

**RESEARCH** The IMF is the leader in globally collaborative myeloma research. The IMF supports lab-based research and has awarded over 100 grants to top junior and senior researchers since 1995. In addition, the IMF brings together the world’s leading experts in the most successful and unique way through the International Myeloma Working Group (IMWG), which is publishing in prestigious medical journals, charting the course to a cure, mentoring the next generation of innovative investigators, and improving lives through better care.

**EDUCATION** The IMF’s educational Patient & Family Seminars, Medical Center Workshops, and Regional Community Workshops are held around the world. These meetings provide up-to-date information presented by leading myeloma specialists and researchers directly to myeloma patients and their families. Our library of more than 100 publications, for patients and caregivers as well as for healthcare professionals, is updated annually and available free of charge. Publications are available in more than 20 languages.

**SUPPORT** Our toll-free Hotline at 800-452-CURE (2873) is staffed by hotline coordinators who answer questions and provide support and information via phone and email to thousands of families each year. The IMF sustains a network of more than 150 support groups and offers training for the hundreds of dedicated patients, caregivers, and nurses who volunteer to lead these groups in their communities.

**ADVOCACY** The IMF Advocacy program trains and supports concerned individuals to advocate on health issues that affect the myeloma community. Working both at the state and federal level, the IMF leads two coalitions to advocate for parity in insurance coverage. Thousands of IMF-trained advocates make a positive impact each year on issues critical to the myeloma community.

Learn more about the way the IMF is helping to improve the quality of life of myeloma patients while working toward prevention and a cure. Contact us at **800-452-CURE** (2873) or visit [myeloma.org](http://myeloma.org).

*Improving Lives • Finding the Cure*